According to Bloomberg, that list would include Perrigo Co., in Ireland and Actelion Ltd, in Switzerland. Both would offer US acquirers the chance to redomicile to friendlier tax environs and cut their corporate rates by up to 1/3. It's all the rage you know having already been done by the likes of Actavis, Jazz, Alkermes, Endo Helath and yes Perrigo. Not to mention recent deals by AbbVie, Mylan, and the failed (but not quite dead yet) Pfizer grab for AZ.
For his part, Actelion CEO Clozel says he's not worried -- emphasized by today's Q2 earnings announcment that the company saw sales go up 17% YoY. Clozel makes his case that its much better for his shareholders to stay independent and continue to count their money. Of course, Shire's Ornskov said the exact same thing publicly up until the moment he agreed to sell Shire for a 49% premium. See Forbes and Fierce Pharma.
Posted by Bruce Lehr July 22nd 2014.